14-day Premium Trial Subscription Sign Up For FreeGet Free

Aldeyra Therapeutics Stock Forecast NASDAQ:ALDX

Price Target and Analyst Ratings

Most Recent Rating

On April 28, 2021 "Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell" gave "" rating for ALDX. The price target was changed from $22.00 to $25.00.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-04-28 Target Raised by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $13.93 $22.00 → $25.00
2021-04-28 Target Raised by Citigroup $13.93 $22.00 → $25.00
2021-04-25 Buy Reiterated by SVB Leerink $10.60 $22.00
2021-03-18 Outperform Initiated by SVB Leerink $11.61 $22.00
2021-03-12 Outperform Initiated by SVB Leerink $12.52 $22.00
2021-03-12 Outperform Initiated by SVB Leerink $12.52
2021-02-08 Buy Initiated by HC Wainwright $12.24 $26.00
2020-12-16 Buy Initiated by Berenberg Bank $7.29 $32.00
2020-11-06 Buy Reiterated by Oppenheimer $6.68
2020-11-06 Overweight Reiterated by Cantor Fitzgerald $6.68
2020-10-30 Buy Initiated by Jefferies Financial Group $6.68 $24.00
2020-10-16 Buy Initiated by BTIG Research $8.10 $29.00
2020-09-22 Buy Initiated by Alliance Global Partners $7.14 $32.00
2020-08-11 Buy Target Lowered by Citigroup $6.61 $24.00 → $22.00
2020-08-07 Buy Reiterated by Oppenheimer $7.13 $15.00
2020-07-07 Buy Initiated by Oppenheimer $4.33 $15.00
2020-05-26 Buy - Market Perform Reiterated by Janney Montgomery Scott $4.11 $28.00
2020-05-26 Buy Reiterated by Laidlaw $4.11 $30.00
2020-05-11 Outperform Initiated by Oppenheimer $2.96

ALDX Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -22.84% during the next 3 months and, with a 90% probability hold a price between $5.36 and $6.92 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-23 $6.90 $7.91 $8.92
2021-09-24 $6.86 $7.87 $8.88
2021-09-27 $6.82 $7.83 $8.84
2021-09-28 $6.78 $7.79 $8.79
2021-09-29 $6.73 $7.74 $8.75
2021-09-30 $6.69 $7.70 $8.71
2021-10-01 $6.65 $7.66 $8.67
2021-10-04 $6.61 $7.62 $8.63
2021-10-05 $6.57 $7.57 $8.58
2021-10-06 $6.52 $7.53 $8.54
2021-10-07 $6.48 $7.49 $8.50
2021-10-08 $6.44 $7.45 $8.46
2021-10-11 $6.40 $7.41 $8.41
2021-10-12 $6.36 $7.36 $8.37
2021-10-13 $6.31 $7.32 $8.33
2021-10-14 $6.27 $7.28 $8.29
2021-10-15 $6.23 $7.24 $8.25
2021-10-18 $6.19 $7.20 $8.20
2021-10-19 $6.14 $7.15 $8.16
2021-10-20 $6.10 $7.11 $8.12
2021-10-21 $6.06 $7.07 $8.08
2021-10-22 $6.02 $7.03 $8.04
2021-10-25 $5.98 $6.99 $7.99
2021-10-26 $5.93 $6.94 $7.95
2021-10-27 $5.89 $6.90 $7.91
2021-10-28 $5.85 $6.86 $7.87
2021-10-29 $5.81 $6.82 $7.83
2021-11-01 $5.77 $6.77 $7.78
2021-11-02 $5.72 $6.73 $7.74
2021-11-03 $5.68 $6.69 $7.70

About Aldeyra Therapeutics

Aldeyra Therapeutics Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. It is developing NS2, a small molecule designed to trap and allow for the degradation of aldehydes. Its product is used for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, sjögren-larsson syndrome, and succinic semi-aldeh... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT